J&J gets positive EU opinion for subcutaneous Rybrevant

EU regulators have issued a positive opinion for the extension of the market authorization for a subcutaneous formulation of Johnson & Johnson’s (NYSE:JNJ) Rybrevant for the treatment of a certain type of lung cancer.

The European Medicines Agency’s Committee for